… 8 and diabetes 9,10 is standard evidence-based practice, the concept of treating obesity to
reduce the risk of cardiovascular … for overweight or obesity improve cardiovascular outcomes. …

… outcome and demonstrates reduced CVD events in persons with obesity and prior CVD
but without diabetes, semaglutide 2.4 mg once weekly treatment should inform obesity …

… whether the cardiovascular outcomes of semaglutide versus … of semaglutide versus placebo
on cardiovascular outcomes … whether the cardiovascular benefits of semaglutide are only …

… In the SELECT cardiovascular outcomes trial, semaglutide showed a 20% reduction in …
established CVD and overweight or obesity but without diabetes. In SELECT, semaglutide was …

… without diabetes. In the present study, we examined the effect of once-weekly semaglutide
2.4 mg on kidney outcomes … Large CVD outcome trials of GLP-1RAs in individuals with type 2 …

… Herein we provide the first insights regarding how sex influences baseline characteristics,
cardiovascular risk, and response to semaglutide in ASCVD and obesity without diabetes. …

… comorbidity and metabolic outcomes over periods ≥ 6 … , and cardiovascular outcomes of 12
months of semaglutide. … metabolic and cardiovascular outcomes achieved by semaglutide in …

… diabetes medications, c-pap machines, anti-hypertensives and improve cardiovascular
outcomes. … in our study include patients not reaching the maximum dose of semaglutide (ie, 1.7 …

… We assessed cardiovascular outcomes of once-daily oral semaglutide in an event-driven,
randomized, double-blind, placebo-controlled trial involving patients at high cardiovascular …

… The primary composite outcome was the first occurrence of cardiovascular death, nonfatal
… We hypothesized that semaglutide would be noninferior to placebo for the primary outcome. …